重组人白细胞介素-11治疗化疗所致血小板减少的临床观察  

Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia

作　　者：雷炜[1] 梁军[1] 陈维刚[1] 马学真[1] 徐梅[1] 杜利力[1] 

机构地区：[1]青岛大学医学院附属医院肿瘤科,266003

出　　处：《中华肿瘤杂志》2006年第7期542-544,共3页Chinese Journal of Oncology

摘　　要：目的观察重组人白细胞介素-11(rhIL-11)治疗化疗所致血小板(PLT)减少的疗效和不良反应。方法采用病例自身对照研究,对第1个周期化疗(对照组)后PLT≤70×109／L的32例实体瘤患者,第2个周期(治疗组)采用相同方案化疗,化疗结束后24 h开始,皮下注射rhIL-11 25μg／kg体重,每天1次,连用7～14 d,或至PLT≥100×109／L时停药。结果治疗组化疗后各时点PLT计数均高于对照组。化疗后,治疗组和对照组PLT最低值分别为(110．2±53．5)×109/L和(55．6±46．8)×109／L,两组差异有统计学意义(P<0．01)。PLT恢复正常时间,治疗组为2～18 d,对照组为5-27 d,中位数分别为5 d和12 d,两组差异有统计学意义(P<0．01)。治疗组中PLT输注2例,次数为2次,对照组为7例9次,差异有统计学意义(P<0．01)。乏力、关节肌肉酸痛、注射部位疼痛、头痛、心悸、水肿和发热等不良反应多为Ⅰ度和Ⅱ度,可自行缓解。Ⅲ度不良反应为乏力、关节肌肉酸痛、头痛,对症处理后可缓解。结论rhIL-11是治疗化疗后PLT减少的有效药物,不良反应可以耐受。Objective To investigate the effectiveness and safety of domestically produced recombinant human interleukin 11 （ rhlL-11 ） for the treatment of chemotherapy-induced thrombocytopenia. Methods A total of 32 solid cancer patients who developed chemotherapy-induced thrombocytopenia （ ≤70 × 10^9/L） after the first cycle of chemotherapy was studied by self-cross control. The patients were given subcutaneous injection of rhlL-11 （25 μg · kg^-1· d^-1 ） for 7 to 14 consecutive days or until platelet count≥ 100 × 10^9/L during the second cycle of chemotherapy using the identical regimen as in the first cycle. Results The mean platelet count of the patients after rhIL-11 treatment was higher at different time points during the second cycle of chemotherapy than that during the first cycle of chemotherapy with the mean platelet count of （ 110. 2 ±53.5） ×10^9/L in the first cycle of chemotherapy versus （55.6 ±46.8） × 10^9/L in the second cycle of chemotherapy （ P 〈 0. 01 ）. Patients with platelet count ≤ 50 ×10^9/L was 4/32 （12.5%） in the first cycle of chemotherapy and 12/32 （37.5%） in the second cycle of chemotherapy （P 〈 0.01 ）. The time recovery to the normal platelet count was 2 - 18 days （median 5 days） in the first cycle of chemotherapy versus 5 -27 days （median 12 days） in the second cycle of chemotherapy （P 〈 0.01）. The case/frequency of the platelet transfusion was 2/2 in the first cycle of chemotherapy, while it was 7/9 in the second cycle of chemotherapy （ P 〈 0.01 ）. The major adverse reactions relative to rhlL-11 treatment were fatigue, myalgia/arthralgia, ache, headache, palpitation, edema and fever, most of which could be relieved automatically without any specific treament. However, some 3 grade side effects such as fatigue, myalgia/arthralgia and headache needed proper medication. Conclusion rhlL-11 is safe and effective for chemotherapy-induced thrombocytopenia with mild and manageable side effects.

关 键 词：白细胞介素-11 血小板减少症/化疗诱导 血小板减少症/治疗 

分 类 号：R730.5[医药卫生—肿瘤]